X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (84) 84
index medicus (77) 77
oncology (71) 71
female (62) 62
male (60) 60
middle aged (54) 54
aged (47) 47
adult (39) 39
human necessities (29) 29
hygiene (29) 29
medical or veterinary science (29) 29
preparations for medical, dental, or toilet purposes (29) 29
cancer (28) 28
aged, 80 and over (27) 27
chemotherapy (27) 27
article (25) 25
mutation (25) 25
treatment outcome (24) 24
care and treatment (21) 21
adenocarcinoma (20) 20
tumors (20) 20
radiotherapy (17) 17
animals (16) 16
surgery (16) 16
antineoplastic combined chemotherapy protocols - therapeutic use (15) 15
mutations (15) 15
research (15) 15
specific therapeutic activity of chemical compounds ormedicinal preparations (15) 15
prognosis (14) 14
survival (14) 14
therapy (14) 14
neoplasm staging (13) 13
protein kinase inhibitors - therapeutic use (13) 13
retrospective studies (13) 13
abridged index medicus (12) 12
analysis (12) 12
cell lung-cancer (12) 12
health aspects (12) 12
antineoplastic agents - therapeutic use (11) 11
pancreatic cancer (11) 11
gemcitabine (10) 10
gene amplification (10) 10
hematology, oncology and palliative medicine (10) 10
lung neoplasms - drug therapy (10) 10
mice (10) 10
neoplasms - drug therapy (10) 10
pharmacology & pharmacy (10) 10
phase-ii (10) 10
pyrazoles - therapeutic use (10) 10
pyridines - therapeutic use (10) 10
carcinoma, non-small-cell lung - drug therapy (9) 9
chemoradiation (9) 9
chemoradiotherapy (9) 9
deoxycytidine - analogs & derivatives (9) 9
expression (9) 9
medicine & public health (9) 9
neoadjuvant therapy (9) 9
pancreatic neoplasms - drug therapy (9) 9
trial (9) 9
adenocarcinoma - genetics (8) 8
capecitabine (8) 8
colorectal cancer (8) 8
disease-free survival (8) 8
dose-response relationship, drug (8) 8
egfr (8) 8
lung neoplasms - genetics (8) 8
metastasis (8) 8
patients (8) 8
survival rate (8) 8
acquired-resistance (7) 7
adenocarcinoma - mortality (7) 7
adenocarcinoma - pathology (7) 7
adenocarcinoma - therapy (7) 7
bevacizumab (7) 7
carcinoma, non-small-cell lung - genetics (7) 7
colorectal neoplasms - drug therapy (7) 7
fluorouracil - administration & dosage (7) 7
gefitinib (7) 7
genetic aspects (7) 7
neoplasms (7) 7
nuclear radiation (7) 7
original reports (7) 7
pancreatic neoplasms - mortality (7) 7
pancreatic neoplasms - pathology (7) 7
proto-oncogene proteins c-met - genetics (7) 7
receptor, epidermal growth factor - genetics (7) 7
stomach cancer (7) 7
young adult (7) 7
activation (6) 6
adenocarcinoma - surgery (6) 6
carcinoma (6) 6
carcinomas (6) 6
colon-cancer (6) 6
colorectal neoplasms - genetics (6) 6
esophageal cancer (6) 6
fluorouracil - analogs & derivatives (6) 6
gene (6) 6
genotype (6) 6
in situ hybridization, fluorescence (6) 6
inhibitor (6) 6
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (203) 203
French (8) 8
Chinese (4) 4
German (4) 4
Korean (2) 2
Portuguese (2) 2
Danish (1) 1
Greek (1) 1
Norwegian (1) 1
Slovenian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2012, Volume 13, Issue 10, pp. 1011 - 1019
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2011, Volume 12, Issue 11, pp. 1004 - 1012
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 09/2009, Volume 27, Issue 26, pp. 4247 - 4253
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 10/2010, Volume 363, Issue 18, pp. 1693 - 1703
A small group of patients with non–small-cell lung cancer have genetic lesions that activate anaplastic lymphoma kinase (ALK). Crizotinib, an orally... 
ALK | MEDICINE, GENERAL & INTERNAL | GEFITINIB | EML4-ALK FUSION GENE | 2ND-LINE TREATMENT | PHASE-II | IDENTIFICATION | TUMORS | ACTIVATING MUTATIONS | EGFR | CHEMOTHERAPY | Lung Neoplasms - drug therapy | Pyrazoles - therapeutic use | Microtubule-Associated Proteins - genetics | Humans | Middle Aged | Receptors, Growth Factor - antagonists & inhibitors | Lung Neoplasms - pathology | Male | Protein Kinase Inhibitors - adverse effects | Protein-Tyrosine Kinases - genetics | Pyridines - adverse effects | Serine Endopeptidases - genetics | Cell Cycle Proteins - genetics | Adult | Female | Pyrazoles - adverse effects | Pyridines - therapeutic use | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Pyridines - administration & dosage | Administration, Oral | Carcinoma, Non-Small-Cell Lung - genetics | Proto-Oncogene Proteins c-met - antagonists & inhibitors | Kaplan-Meier Estimate | In Situ Hybridization, Fluorescence | Receptor Protein-Tyrosine Kinases | Disease Progression | Protein Kinase Inhibitors - administration & dosage | Pyrazoles - administration & dosage | Oncogene Proteins, Fusion - genetics | Protein Kinase Inhibitors - therapeutic use | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Protein-Tyrosine Kinases - antagonists & inhibitors | Tyrosine | Care and treatment | Lung cancer, Small cell | Genetic aspects | Diagnosis | Health aspects | Phosphotransferases | Lymphomas | Pharmaceutical industry | Lung cancer | Tumors
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 03/2012, Volume 30, Issue 8, pp. 863 - 870
Journal Article
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 12/2011, Volume 29, Issue 36, pp. 4803 - 4810
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 06/2009, Volume 27, Issue 18, pp. 3027 - 3035
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 01/2014, Volume 32, Issue 2, pp. 68 - 75
Purpose Human epidermal growth factor (HER) -mediated signaling is critical in many cancers, including subsets of breast and lung cancer. HER family members... 
CELL LUNG-CANCER | HKI-272 | THERAPY | TRASTUZUMAB | ONCOLOGY | METASTATIC BREAST-CANCER | TYROSINE KINASE INHIBITOR | HER2 STATUS | MUTATIONS | EXPRESSION | EGFR | Neoplasms - metabolism | Lung Neoplasms - drug therapy | Nausea - chemically induced | Receptor, ErbB-2 - genetics | TOR Serine-Threonine Kinases - metabolism | Area Under Curve | Humans | Lung Neoplasms - metabolism | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Receptor, ErbB-2 - metabolism | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Phosphatidylinositol 3-Kinases - metabolism | Diarrhea - chemically induced | Quinolines - administration & dosage | Breast Neoplasms - metabolism | Dose-Response Relationship, Drug | Quinolines - pharmacokinetics | Neoplasms - genetics | Female | Sirolimus - adverse effects | Lung Neoplasms - genetics | Sirolimus - analogs & derivatives | Anemia - chemically induced | Treatment Outcome | Sirolimus - pharmacokinetics | Breast Neoplasms - drug therapy | Neoplasms - drug therapy | Sirolimus - administration & dosage | Breast Neoplasms - genetics | Gene Amplification | Signal Transduction - drug effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Stomatitis - chemically induced | Aged | Mutation | Quinolines - adverse effects | Index Medicus
Journal Article
Journal Article